Menu

Spheroid Cell Culture: New Dimensions in 3-D Assays

The Scientist is bringing together a panel of experts to discuss the value of spheroid culture systems, and to explore the technical benefits and challenges of making the switch from 2-D to 3-D culture.

Aug 3, 2017
The Scientist Creative Services Team

Spheroid Cell Culture: New Dimensions in 3D Assays from thescientistllc on Vimeo.

High attrition in clinical trials and the need to replace animal models in a variety of applications has driven researchers to develop in vitro assays with greater physiological relevance. The last decade has seen a large variety of models developed to mimic cells organized into tissues and even organs. These have collectively been termed 3-D cell culture models. 3-D methods are deemed superior to growing cells in a monolayer due to increased extracellular matrix (ECM) formation, cell-to-cell and cell-to-matrix interactions, all important for differentiation, proliferation and cellular functions in vivo. Currently, the most popular method of 3-D cell culture is aggregating cells into spheroids. The Scientist is bringing together a panel of experts to discuss the value of spheroid culture systems, and to explore the technical benefits and challenges of making the switch from 2-D to 3-D culture. Attendees will have the opportunity to interact with the experts, ask questions, and seek advice on topics that are related to their research.

Topics to be covered:

  • Using 3-D culture to turn individual cells into organoids and organs
  • Novel options for 3-D culture scaffolding

Meet the Speakers:

Esmaiel Jabbari, PhD  
Professor, Chemical Engineering, Biomedical Engineering
College of Engineering and Computing, University of South Carolina

 

 

Margaret Magdesian, PhD  
Founder and CEO
Ananda Devices

 

 

 

 

 

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.